Denali Therapeutics Statistics

Total Valuation

DNLI has a market cap or net worth of $3.32 billion. The enterprise value is $2.09 billion.

Market Cap	3.32B
Enterprise Value	2.09B

Important Dates

The next estimated earnings date is Tuesday, February 25, 2025, before market open.

Earnings Date	Feb 25, 2025
Ex-Dividend Date	n/a

Share Statistics

DNLI has 143.92 million shares outstanding. The number of shares has increased by 15.04% in one year.

Current Share Class	143.92M
Shares Outstanding	143.92M
Shares Change (YoY)	+15.04%
Shares Change (QoQ)	+0.37%
Owned by Insiders (%)	4.68%
Owned by Institutions (%)	88.99%
Float	130.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	57.86
PB Ratio	2.51
P/TBV Ratio	2.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.98, with a Debt / Equity ratio of 0.04.

Current Ratio	9.98
Quick Ratio	9.62
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5,125.04

Financial Efficiency

Return on equity (ROE) is -35.09% and return on invested capital (ROIC) is -25.19%.

Return on Equity (ROE)	-35.09%
Return on Assets (ROA)	-23.81%
Return on Capital (ROIC)	-25.19%
Revenue Per Employee	n/a
Profits Per Employee	-$960,658
Employee Count	445
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, DNLI has paid $30,000 in taxes.

Income Tax	30,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +34.23% in the last 52 weeks. The beta is 1.39, so DNLI's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	+34.23%
50-Day Moving Average	23.65
200-Day Moving Average	23.12
Relative Strength Index (RSI)	55.83
Average Volume (20 Days)	1,076,090

Short Selling Information

The latest short interest is 7.84 million, so 5.45% of the outstanding shares have been sold short.

Short Interest	7.84M
Short Previous Month	7.46M
Short % of Shares Out	5.45%
Short % of Float	6.03%
Short Ratio (days to cover)	9.04

Income Statement

Revenue	n/a
Gross Profit	-412.36M
Operating Income	-512.50M
Pretax Income	-419.62M
Net Income	-427.49M
EBITDA	-511.85M
EBIT	-512.50M
Earnings Per Share (EPS)	-$2.73

Full Income Statement

Balance Sheet

The company has $836.56 million in cash and $52.57 million in debt, giving a net cash position of $1.23 billion or $8.54 per share.

Cash & Cash Equivalents	836.56M
Total Debt	52.57M
Net Cash	1.23B
Net Cash Per Share	$8.54
Equity (Book Value)	1.32B
Book Value Per Share	9.17
Working Capital	781.75M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$362.64 million and capital expenditures -$13.06 million, giving a free cash flow of -$375.69 million.

Operating Cash Flow	-362.64M
Capital Expenditures	-13.06M
Free Cash Flow	-375.69M
FCF Per Share	-$2.61

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DNLI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.04%
Shareholder Yield	-15.04%
Earnings Yield	-12.89%
FCF Yield	-11.33%

Dividend Details

Analyst Forecast

The average price target for DNLI is $38.91, which is 68.88% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$38.91
Price Target Difference	68.88%
Analyst Consensus	Strong Buy
Analyst Count	13
Revenue Growth Forecast (5Y)	19.99%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

DNLI has an Altman Z-Score of 11 and a Piotroski F-Score of 1.

Altman Z-Score	11
Piotroski F-Score	1